UbiVac

UbiVac is a clinical stage biotech engaged in research and development and manufacture of therapeutic immune activators, vaccines and cellular immunotherapies

[UbiVac @UbiVac]

Thrilled that @UbiVac ‘s DPV-001, the 1st #DarkMatter #cancer #Immunotherapy in the clinic, is improving response rate & progression-free survival for patients with head & neck squamous cell cancer #HNSCC / @incyte
Today #SITC2024 poster #1481
https://t.co/flLOznMDOG

[Testicular Cancer @TestesCancer]

Grateful for this year’s speakers presenting at our 10th annual Testicular Cancer Conference presented by @FennecPharma being held at @harvardmed in collaboration with @MassGenBrigham, @DanaFarber, and @Harvard

Visit our website to see the full lineup of incredible speakers at https://t.co/0Fp8fZsFGm

#testicularcancer #UroSoMe #urology #menshealth

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC commentary: Next-generation multiplex-edited CAR-NK cells: more edits, more power? https://t.co/t675Lmk3el
@TobiasBexte @dlwagner13

[FDA Oncology @FDAOncology]

Want to lower your cancer risk? Start here:
✅ Eat healthy
🚭 Avoid smoking & limit alcohol
🏃‍♀️ Stay active
🌞 Protect your skin
🩺 Get screened early
Small steps = powerful prevention. #CancerPrevention #NationalCancerControlMonth

[FDA Oncology @FDAOncology]

Today, FDA Oncology Center Director Richard Pazdur, MD, accepted the @AACR 2025 Enduring Impact Award for Transformative Service to Cancer Science and Medicine from his former mentee, AACR President Dr. Patricia LoRusso, during the #AACR25 Annual Meeting Opening Ceremony.

[Dr. Patrick Hwu @PatrickHwuMD]

Had the best time performing with @sitcancer’s band, #TheCheckpoints @AACR annual reception last night! #AACR25 🤘🎹

@RPachynski @jasonlukemd @ipimama123 @BReinfeld @sitcancer @DocsWhoRock

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

A great day for patients & the field! @DrUppaluri presents data from KN689 showing improved survival (HR=0.66) & major pathologic responses (~10%) in resectable locally advanced HNSCC treated w perioperative pembrolizumab. These data will result in a new standard of care. @AACR

[Governor JB Pritzker @GovPritzker]

As Governor of Illinois, my oath is to the Constitution of our state and our nation.

We don’t have kings in America, and I won’t bend the knee to one.

[Bernard A Fox @BernardAFox]

Appreciate @oncodaily⁩ publishing LinkedIn post highlighting world’s 1st cancer’s #DarkMatter #immunotherapy! This strategy has tripled response rates! ⁦@UbiVac⁩ looking to move this off-the-shelf drug to other #cancers ⁦@ChilesResearch⁩ https://t.co/XCqHkQF8xP

[Nature Reviews Cancer @NatureRevCancer]

#REVIEW 🚨

Hanahan, Michielin & Pittet discuss how, nearly all cell types in the tumour microenvironment can be programmed to mediate — as functionally distinct subtypes — immunosuppressive programmes.

📖 👇
https://t.co/QQ8ZELaraO

[ZERO Prostate Cancer @ZEROCancer]

🚨 BREAKING: Sens. @CoryBooker & @JohnBoozman introduce bipartisan PSA Screening for HIM Act (S. 297)!

This bill would eliminate cost barriers for high-risk men seeking prostate cancer screening.

Early detection saves lives. Cost shouldn't be a barrier. 💙

[Penn Medicine @PennMedicine]

CAR T cells have cured cancer for many patients. But the current treatment process is a laborious (and expensive) one. That's why @carlhjune teamed up with @WeissmanLab to explore using #mRNAvaccines to help a patient's own body create the #CARTcells needed to fight cancer.

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

RIP President Carter. Diagnosed with metastatic melanoma in 2015, he was declared cancer-free a few months later thanks to #immunotherapy & lived to 100. This remarkable outcome gave hope to countless others with cancer who continue to live, love & work towards a better world.

[Omid Hamid MD @OmidHamidMD]

#SITC24 @BernardAFox recognized with well deserved @sitcancer lifetime achievement award. A strong leader and friend. Beacon of progress. Congrats my friend!!! @ProvHealth

[Bernard A Fox @BernardAFox]

💥 #Cancer #Vaccines in combo IO are #HOT!! See @romleidner at noon today Poster #1481 #SITC2024 /56% RR in PD-1 naïve & 33% RR in PD-1 experienced #HNSCC/18 patients treated. SOME COOL TCR & #LAG3 data/ https://t.co/dFerr0BByr
@UbiVac @incyte @ChilesResearch @John_E_Connolly

[Parker Institute for Cancer Immunotherapy @parkerici]

#Glioblastoma (GBM) is one of the most difficult cancers to treat, in part due to its immunosuppressive tumor microenvironment in which TGF-β protects the tumor. Research in @OUPAcademic’s Neuro-Oncology journal unveils a strategy to overcome this: https://t.co/RgnvGh5soN (1/3)

[DrORourke @DrORourke2]

This is a massive overreach - AI driven discovery does not account for biological complexity which is the major challenge in drug evaluation and approval

[DrORourke @DrORourke2]

Our group recently also showed that TGFb disruption enhanced our bivalent CART cell approach currently in P1 for recurrent #glioblastoma https://t.co/8TRuTqhP7F

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Honored to join this morning the indefatigable @roth_becky at @KATUNews for AM Northwest to discuss cancer research @providence & the “mother of all relays”, #HoodToCoast, which starts this Friday. Thank you @RaptisHelen!
#FinishCancer @ChilesResearch
https://t.co/rQu9v8ehqX

[Jason Mast @Jasonmmast]

Vir Biotechnology announced today it's all but abandoning infectious disease research and pivoting to cancer.

My story from May on how a grand, billion-dollar plan to build a company to create "a world without infectious disease" fell apart:

https://t.co/jboFQYyWFQ